Literature DB >> 25308726

Elevated concentration of C-reactive protein is associated with pregnancy-related co-morbidities but not with relapse activity in multiple sclerosis.

Anna Jalkanen1, Tommi Kauko, Janne O Koskinen, Matti E Waris, Laura Airas.   

Abstract

During pregnancy, alterations take place in mother's immune system with the goal of maintaining a successful pregnancy, and delivering healthy offspring. Immune alterations include activation of the innate immune system and dampening of cell-mediated adaptive immunity. Due to these alterations, cell-mediated autoimmune diseases typically ameliorate during pregnancy. The objectives of this study were to evaluate whether C-reactive protein (CRP) concentration, a sensitive marker of systemic inflammation (1) is increased during MS pregnancy (2) predicts pregnancy-related co-morbidities associated with MS (3) predicts MS disease activity after delivery. CRP concentration was measured using a high sensitivity assay from seven prospectively collected serum samples of 41 MS patients and 19 controls during pregnancy and 6 months after delivery. Annualized relapse rates, EDSS, fatigue scores and obstetric details of the patients were recorded. Delivery-related CRP levels were significantly elevated both among MS patients and in controls. CRP levels were higher during pregnancy than during the postpartum period in both study groups. Delivery-related elevated CRP levels did not correlate with postpartum disease activity. MS patients with eventual gestational diabetes had a significantly higher median CRP in the beginning of pregnancy compared to non-diabetic MS patients (9.28 vs. 2.98 mg/l, p = 0.0025). MS patients reporting fatigue had a significantly higher CRP throughout pregnancy compared to patients without fatigue. Higher CRP values were associated with pregnancy-related co-morbidities but not with MS disease activity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25308726     DOI: 10.1007/s10072-014-1980-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  39 in total

1.  Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland.

Authors:  A Jalkanen; A Alanen; L Airas
Journal:  Mult Scler       Date:  2010-06-11       Impact factor: 6.312

2.  Gestational diabetes and subclinical inflammation: evaluation of first year postpartum outcomes.

Authors:  Ufuk Ozuguz; Serhat Isik; Dilek Berker; Ayse Arduc; Yasemin Tutuncu; Gulhan Akbaba; Ferhat Gokay; Serdar Guler
Journal:  Diabetes Res Clin Pract       Date:  2011-09-13       Impact factor: 5.602

3.  Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study.

Authors:  Maria Giovanna Marrosu; Eleonora Cocco; Marina Lai; Gabriella Spinicci; Maria Paola Pischedda; Paolo Contu
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

4.  Increased thyroid autoimmunity among women with multiple sclerosis in the postpartum setting.

Authors:  A Jalkanen; M Saraste; A Gfeller; H M Surcel; L Airas
Journal:  Mult Scler       Date:  2013-04-29       Impact factor: 6.312

Review 5.  The systemic response to brain injury and disease.

Authors:  Daniel C Anthony; Yvonne Couch; Patrick Losey; Matt C Evans
Journal:  Brain Behav Immun       Date:  2011-11-09       Impact factor: 7.217

Review 6.  Physiopathology of fatigue in multiple sclerosis.

Authors:  Letizia Leocani; Bruno Colombo; Giancarlo Comi
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

7.  Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder?

Authors:  Emily C Somers; Sara L Thomas; Liam Smeeth; Andrew J Hall
Journal:  Am J Epidemiol       Date:  2009-02-18       Impact factor: 4.897

8.  Prenatal and perinatal factors and risk of multiple sclerosis.

Authors:  Hannah Gardener; Kassandra L Munger; Tanuja Chitnis; Karin B Michels; Donna Spiegelman; Alberto Ascherio
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

9.  Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis.

Authors:  G Giovannoni; D H Miller; N A Losseff; M Sailer; N Lewellyn-Smith; A J Thompson; E J Thompson
Journal:  J Neurol       Date:  2001-06       Impact factor: 4.849

10.  Fatigue is not associated with raised inflammatory markers in multiple sclerosis.

Authors:  G Giovannoni; A J Thompson; D H Miller; E J Thompson
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

View more
  2 in total

1.  Advances in clinical neurology through the journal "Neurological Sciences" (2015-2016).

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2017-01       Impact factor: 3.307

Review 2.  An evaluation of the recognised systemic inflammatory biomarkers of chronic sub-optimal inflammation provides evidence for inflammageing (IFA) during multiple sclerosis (MS).

Authors:  Christopher Bolton
Journal:  Immun Ageing       Date:  2021-04-14       Impact factor: 6.400

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.